ABOUT ONCOTARGET.ORG:
Find the latest articles about new and trending peer-reviewed scientific papers published by Oncotarget – a rigorously reviewed, weekly open access scientific journal focusing on all topics surrounding cancer research, and part of the Impact Journals family of scientific publications. Visit Oncotarget.net to learn about our community-based news and events.
ABOUT ONCOTARGET:
Oncotarget is published by Impact Journals of Orchard Park, New York. Impact Journals has a proven track record for reaching the standards of the Wellcome Trust Publisher Requirements and was included into the Wellcome Trust List of Compliant Publishers.
The Editorial Board of Oncotarget is honored to feature several Nobel Prize winners. The Editorial Board also features winners of prestigious recognitions such as the Lasker Award and the Breakthrough Prize.
Oncotarget utilizes an open-access model. This means that the peer-reviewed research articles published in Oncotarget are distributed online, free of cost or other access barriers. Oncotarget’s mission has always been to make exceptional discoveries rapidly and widely available, eliminate borders between specialties by linking different fields of biomedical science to foster the applications of basic and clinical science
Dr. Mikhail (Misha) Blagosklonny and Dr. Andrei Gudkov are the two founding Editors-in-Chief of Oncotarget. They both have a history of producing some of the finest medical research. Dr. Gudkov is focusing on developing and applying new technologies for functional gene discovery, which will lead to designing new therapeutic approaches to cancer treatment. Dr. Blagosklonny, well-known for his expertise in cancer and aging research. He has published dozens of experimental and theoretical papers that encompassed two important subjects: selective killing cancer cells with deregulated cell cycle or drug resistance by exploiting their resistance and the hyperfunction (or quasi-programmed) theory of aging. In its turn, this theory helped to rediscover Rapamycin as a well-tolerated anti-aging drug.
CONTACT INFORMATION:
Those who want to receive updates from the doctor in real-time can follow him on Twitter @Blagosklonny. Dr. Blagosklonny also regularly updates his personal website, which can be visited here.
For those interested in learning more about Oncotarget or in contacting the Journal, please visit the website. You can also follow Oncotarget on Twitter @Oncotarget.
